Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Multiple Myeloma
100%
Prognostic Impact
100%
Thalidomide
100%
Inflammatory Factors
100%
Confidence Interval
60%
Relative Risk
60%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
40%
Induction Chemotherapy
40%
Independent Prognostic Factor
40%
South Korea
20%
Multivariate Analysis
20%
Overall Survival
20%
Albumin
20%
University Hospital
20%
Prognosis Prediction
20%
Platelet Count
20%
C-reactive Protein
20%
Lactate Dehydrogenase
20%
Progression-free Survival
20%
Male-to-female Ratio
20%
β2-microglobulin (β2-MG)
20%
Absolute Lymphocyte Count
20%
Medicine and Dentistry
Multiple Myeloma
100%
Thalidomide
100%
Prognostic Factor
66%
Autologous Stem Cell Transplantation
66%
Induction Chemotherapy
66%
Platelet
33%
Lactate Dehydrogenase
33%
Albumin
33%
Overall Survival
33%
Progression Free Survival
33%
C Reactive Protein
33%
Lymphocyte
33%
Multivariate Analysis
33%
Biochemistry, Genetics and Molecular Biology
Autologous Stem Cell Transplantation
100%
Multivariate Analysis
50%
Microglobulin
50%
Overall Survival
50%
Platelet Count
50%
Lymphocyte Count
50%
Progression Free Survival
50%
C-Reactive Protein
50%
Lactate Dehydrogenase
50%
Albumin
50%
Immunology and Microbiology
Thalidomide
100%
Multiple Myeloma
100%
Autologous Stem Cell Transplantation
66%
Platelet Count
33%
Overall Survival
33%
Lymphocyte Count
33%
Progression Free Survival
33%
C-Reactive Protein
33%
Albumin
33%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Thalidomide
100%
Chemotherapy
66%
Overall Survival
33%
C Reactive Protein
33%
Progression Free Survival
33%
Lactate Dehydrogenase
33%
Albumin
33%
Neuroscience
Thalidomide
100%
Stem Cell
66%
C-Reactive Protein
33%
Albumin
33%
Lactate Dehydrogenase
33%
Lymphocyte
33%
Platelet
33%